Endocrine-Sensitive Disease Rate in Postmenopausal Patients with Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial

Cynthia X. Ma, Vera J. Suman, Souzan Sanati, Kiran Vij, Meenakshi Anurag, A. Marilyn Leitch, Gary W. Unzeitig, Jeremy Hoog, Aranzazu Fernandez-Martinez, Cheng Fan, Richard A. Gibbs, Mark A. Watson, Travis J. Dockter, Olwen Hahn, Joseph M. Guenther, Abigail Caudle, Erika Crouch, Amy Tiersten, Monica Mita, Wajeeha RazaqTina J. Hieken, Yang Wang, Mothaffar F. Rimawi, Anna Weiss, Eric P. Winer, Kelly K. Hunt, Charles M. Perou, Matthew J. Ellis, Ann H. Partridge, Lisa A. Carey

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Endocrine-Sensitive Disease Rate in Postmenopausal Patients with Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences